Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Kory Kantenga from LinkedIn unpacks how the US added nearly 3x the expected jobs in March, and whether it can last as the Iran war reshapes the economy.
U.S. Air Force pilot Tyler Lucas beat 199 competitors on Beast Games Season 2 to win $5.1M. He joins us live to share how discipline and loyalty won the game.
Osier founder Cheree Ashley spent a decade building recovery programs & now she's channeling that mission into skincare with Selling Sunset's Sandra Vergara.
Genesis just committed to 22 new vehicles by 2030. The brand's COO joins us live to break down their luxury takeover, NY Auto Show reveals, and what's next.
Super League is redefining brand advertising, inside Roblox and Minecraft, reaching 300M gamers with results traditional ads can't touch. Here's how they do it.
As OpenAI and Anthropic eye public markets, Mizuho analyst Lloyd Walmsley tells us which AI giant has the stronger case for investors and what to watch next.
